Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibitor durvalumab in patients with extensive-stage small cell lung cancer (SCLC) (Abstract LBA8005).
Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radiotherapy. C-POST evaluated adjuvant cemiplimab-rwlc for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6083).
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s meeting. The first focuses on a post hoc analysis of the phase III DeLLphi-304 trial (Abstract 8006), which looked at the intracranial efficacy of tarlatamab in the second line; the second evaluated concurrent thoracic radiotherapy, chemotherapy, and durvalumab in extensive-stage disease (Abstract LBA8005).
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, adjuvant pembrolizumab for 1 year approximately doubled disease-free survival, causes fatigue and dyspnea which modestly impacted physical function and ability to perform certain roles (such as work and hobbies), without impact on overall quality of life (Abstract 4513).
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
